



Research report

Evaluating the validity of blood-based membrane potential changes for the identification of bipolar disorder I

Alagu P. Thiruvengadam^{a,*}, Krish Chandrasekaran^b

^a University of Maryland School of medicine, Baltimore MD, USA

^b Department of Anesthesiology, University of Maryland School of Medicine, Baltimore MD, USA

Received 1 January 2006; received in revised form 14 September 2006; accepted 27 September 2006

Abstract

Objective: The objective of this study was to develop a diagnostic blood test for bipolar disorder I using membrane potentials as biological markers.

Methods: We measured the fluorescence intensity of a dye sensitive to membrane potential in whole blood samples from bipolar I, unipolar, schizophrenic patients, and psychiatrically normal controls. Patients were diagnosed through structured clinical interviews according to DSM-IV. Both the *t*-test and logistic regression analysis were used to analyze the data.

Results: The membrane potential as indicated by the fluorescence intensity of the membrane potential dye in blood cells drawn from patients with bipolar disorder I was significantly different from the blood cells drawn from unipolar and schizophrenic patients, and from psychiatrically normal controls ($P < 0.001$). The specificity and sensitivity were determined to be 0.88 and 0.78 respectively which compared well with the state of the art diagnostic techniques for other diseases. Logistic regression analysis revealed that the membrane potential was a reliable predictor which could be used as a diagnostic marker for bipolar I.

Conclusions: These results indicate that the membrane potential of blood cells can be used as a diagnostic marker to augment the DSM-IV diagnosis of bipolar disorder I. Expanded clinical trials are needed to establish this technique for general use.

© 2006 Elsevier B.V. All rights reserved.

Keywords: Bipolar disorder I; Membrane potential; Whole blood cells; Diagnostic tests; Sensitivity; Specificity

1. Introduction

The diagnosis of bipolar disorder can be difficult and many patients can go undiagnosed or misdiagnosed for a decade or more. There is a need for a clinical blood test to augment the DSM IV diagnosis (Lish et al., 1994; Suppes et al., 2001; Hirschfeld et al., 2003; Ghaemi et al., 2000) among others and misdiagnosis of bipolar illness can have

adverse consequences on the course of the illness. Given the wealth of literature suggesting a biologic and/or genetic abnormality in this disorder, a biological diagnostic test would be a reasonable expectation.

Sodium and potassium-activated adenosine triphosphatase, (Na^+ , K^+ -ATPase or sodium pump), whose activity is essential to maintain the homeostasis of membrane potential, has been investigated for its possible involvement in the pathophysiology of bipolar disorder I (cf Mallakh and Wyatt, 1995). However, this has been an unsettled and controversial subject in the field for many years. Na^+ , K^+ -ATPase activity has been

* Corresponding author. 11862 Farside Road, Ellicott City, MD, 21042 USA. Tel.: +1 410 730 6767.

E-mail address: Thiruvengadam@jhu.edu (A.P. Thiruvengadam).

variously reported to be increased, decreased, or unchanged in bipolar patients. In 1997, Looney et al. conducted a meta-analysis of the available literature on erythrocyte Na^+ , K^+ -ATPase activity in bipolar disorder patients and concluded that it is lower in bipolar patients (Looney and el Mallakh, 1997). The question of exactly how the Na^+ , K^+ -ATPase plays a role in bipolar disorder remains unanswered. El-Mallakh et al. measured the trans-membrane potential in leukocytes from hospitalized bipolar patients and observed that the trans-membrane potentials in lymphocytes of the bipolar patients were hyperpolarized compared with normal controls and euthymic patients on lithium (el Mallakh et al., 1996). However, Buss et al. measured the membrane potentials of cultured lymphoblasts and concluded that there was no significant difference in membrane potentials in lymphoblasts among bipolar patients, their siblings and normal controls (Buss et al., 1996). Recently Thiruvengadam analyzed the role of lithium in depolarizing the resting membrane potential of neurons using the Goldman–Hodgkin–Katz equation for membrane potential and showed that the addition of lithium would depolarize the membrane potential (Thiruvengadam, 2001, 2004).

In addition, a smaller but significant increase in Na^+ , K^+ -ATPase density (number of molecules/unit area) after incubation for 72 h in ethacrynate (a diuretic), or in lithium has been observed in blood cells drawn from bipolar I patients compared to blood cells from unaffected individuals (Wood et al., 1991). Cherry and Swann showed that the potassium uptake in cultured lymphoblasts from affected bipolar patients was much lower as compared to that of siblings as well as matched normal subjects (Cherry and Swann, 1994). Li and El-Mallakh found that ethacrynate-treated lymphoblastoid cells from bipolar individuals were unable to up-regulate Na^+ , K^+ -ATPase as do cells from psychiatrically normal controls (Li and el Mallakh, 2004). These results suggest that the changes in membrane potential, reflecting the changes in Na^+ , K^+ -ATPase regulation, may occur in blood cells of affected patients compared to those in unaffected control subjects.

Our preliminary results indicated that the membrane potentials of cultured lymphoblasts from bipolar patients were significantly different from that of controls and siblings. Such direct measurements of membrane potentials using fluorescent dyes are subject to several limitations as discussed later in this paper. This led us to develop a ratio method in which we measured the fluorescence intensity of a membrane potential dye in cultured lymphoblasts obtained from controls, siblings and bipolar patients in a reference (sometimes called regular) buffer, in a K^+ -free buffer (reference buffer minus K^+), and in the K^+ -free buffer with ethacrynate. The ratios of fluorescence intensity

between cells incubated in K^+ -free buffer over reference buffer and those of cells incubated in K^+ -free buffer with ethacrynate over reference buffer were determined. These ratios were significantly different in bipolar patients as compared to those from controls and siblings. We also tested whether similar changes occur in blood cells of bipolar patients and evaluated whether these changes would have a diagnostic use.

2. Methods

2.1. Cell cultures

Immortalized lymphoblasts from bipolar patients, their siblings and controls were obtained from the Human Genetic Mutant Cell Repository (Coriell Institute for Medical Research, Camden NJ). Six samples of cells each from bipolar patients, their siblings and unrelated control subjects were used. These cells were grown at 37 °C in RPMI 1640 culture medium (GIBCO, Life Technologies, Gaithersburg, MD, USA) with 15% fetal bovine serum and $1 \times$ penicillin/streptomycin.

2.2. Membrane potential measurements

Cultured cells grown in suspension were centrifuged at $210 \times g$ for 5 min at room temperature and the cell pellets were suspended in 3 ml of reference buffer (5 mM KCl, 4 mM NaHCO_3 , 5 mM HEPES, 134 mM NaCl, 2.3 mM CaCl_2 , and 5 mM glucose). Cells were counted and the required number of cells was suspended in 3 ml of reference buffer. The cells were incubated with a voltage sensitive fluorescent dye [3, 3'-dihexyloxacarbocyanine iodide [DiOC6 (3) (Molecular Probes Inc. Eugene, OR, USA)] for 30 min at room temperature. The cell suspension was centrifuged and re-suspended in the same buffer without the dye. Membrane potential as indicated by the fluorescence intensity of the dye was measured using a fluorescence spectrometer (F2500 Hitachi, Japan). The intensity of fluorescence was measured at an excitation wavelength of 488 nm and emission at 530 nm. The time of recordings varied from 10 s to 1500 s depending upon the experiment.

The fluorescent dye, DiOC6(3), is used to measure plasma and mitochondrial membrane potential. However, the concentration of the dye that is used to measure mitochondrial membrane potential is < 1 nM (Rottenberg and Wu, 1998). In our experiments we used the dye at μM concentrations. It is documented that DiOC6(3) mostly reports plasma membrane potential changes at concentrations higher than 40 nM, whereas at concentrations lower than 1 nM it mostly reports mitochondrial membrane

Table 1
Patient demographics for blind trials

Ethnicity and gender	Total	Bipolar I	Unipolar	Schizophrenic	Control	Age (yrs)
White Male (WM)	23	9	4	3	7	18–67
White Female (WF)	21	14	2	2	3	18–65
Black Male (BM)	6	0	0	4	2	30–60
Black Female (BF)	12	3	6	1	2	30–60
Asian Male (AM)	3	0	0	0	3	25–35
Asian Female (AF)	2	1	0	0	1	35–45
Total	67	27	12	10	18	

potential changes (Nicholls and Ward, 2000). Thus it appears that the positively charged dye at lower concentrations partitions more into mitochondria due to the higher negative potential of mitochondria whereas at higher concentrations the fluorescence intensity might represent the negative potentials of both mitochondria and plasma membrane. In addition, this dye has been used previously by other investigators to measure membrane potential of erythrocytes and lymphocytes including bipolar cells (Pratap et al., 1990; Waczulikova et al., 2000; el Mallakh et al., 1996).

We used a ratio method which eliminates distortions of data caused by photo bleaching and variations in probe loading and retention, as well as instrumental factors such as illumination stability and sensitivity of the detector. The ratio indicates the differences in the potentials among specific samples in two different buffers under identical conditions. Our approach is based on the following considerations:

The relationship between fluorescence intensity and membrane potential can be stated as

$$I = CV \quad (1)$$

where I is the fluorescence intensity, V is the membrane potential, and C is the proportionality constant. The proportionality constant C depends upon the dye loading, cell concentration, temperature and other experimental errors. By doing experiments in two different buffers (regular and K^+ -free) simultaneously we cancel out C as shown below:

$$I_1 = CV_1 \quad (2)$$

for the first measurement and

$$I_2 = CV_2 \quad (3)$$

for the second measurement.

If we take a ratio between Eqs. (3) and (2) we get

$$\frac{I_2}{I_1} = \frac{V_2}{V_1} \quad (4)$$

For ratio measurements, equal volumes of cell suspension were added to either the reference buffer or the K^+ -free buffer or the K^+ -free buffer with ethacrynate and incubated with the dye for 30 min. The intensity of fluorescence was then measured under identical conditions except for the buffer. We found that the treatment with ethacrynate would augment the difference in the ratio of fluorescence intensity of the membrane potential dye in bipolar subjects compared to other subjects. Therefore, the fluorescence intensity ratio in K^+ -free buffer with ethacrynate (at pH=6.8) over that in reference (regular) buffer (at pH=7.4) was used in the clinical trials.

2.3. Clinical trial

The clinical trial was performed strictly following the regulations and guidelines of the Internal Review Board (IRB). Informed consent of each subject was obtained before the blood was drawn. The confidentiality of the patient records was ensured according to the IRB procedures. The investigator performing the membrane potential measurements knew only the sample number but not the patient history or the diagnosis. The study included blood samples from patients diagnosed as bipolar disorder I ($n=27$), major depression ($n=12$), schizophrenia ($n=10$), and psychiatrically normal controls ($n=18$). Table 1 shows the ethnicity and gender of these blind trial groups. A total of 67 samples including 32 males and 35 females were tested. 18 were normal controls with no known psychiatric illness and 49 were patients. Of the 49 patients, 30 were inpatients who were stabilized and on medication during blood draw. The remaining 19 were outpatients under the care of a clinical psychiatrist in the local community. The ages ranged from 21 to 70 years. Seventeen of the bipolar patients were on lithium while 9 were on valproate and one was on topiramate after electroconvulsive therapy. Two of the bipolar patients were diabetics. If a patient matched a diagnosis, structured clinical interviews according to DSM-IV guidelines were performed (Bowden, 2002).

Whole blood samples were drawn from the subjects and were stored at 4 °C. All the samples were tested within 24 h. The membrane potentials were measured both in the K⁺ free buffer with ethacrynate and in the reference buffer without ethacrynate. First fluorescent dye was added to both suspensions simultaneously and incubated for 30 min. Then the cell suspension loaded with the dye was centrifuged, drained and re-suspended in the respective buffers. The intensity of fluorescence was measured for 10 seconds and the ratio of the intensity in the K⁺-free buffer with ethacrynate over the intensity in the reference (regular) buffer was calculated.

2.4. Statistical analysis

Based on the results obtained in the open trial, we determined the sample size to be 5 with a power of 0.9, an alpha of 0.05, difference in mean of 0.08, and a standard deviation of 0.03. However, we conservatively tested a total of 67 samples including 18 normal controls, 10 schizophrenics, 12 unipolars and 27 bipolar I (40 non-bipolars and 27 bipolars). The statistical significance of the differences between bipolar groups and non bipolar groups was determined by *t*-test (15). Logistic regression was used to assess the predictive power of the membrane potential ratios for the various

diagnoses (16). A binomial logistic regression model can be used to calculate the probability that the “patient” is bipolar I or not. Binomial logistic regression is a form of regression which is used when the dependent variable is dichotomous and the independents are of any type (Tabachnick and Fidell, 2001). Logistic regression applies maximum likelihood estimation after transforming the dependent into a logit variable (the natural log of the odds of the dependent occurring or not). The logit for these data is given by:

$$\text{Logit } P = 997.042 - (1223.223 \cdot \text{BPDMEAN}) \quad (5)$$

where logit *P* is the linear portion of the regression equation which is used to create the predictor model and BPDMEAN is the mean of the ratios for the “patient”. The probability equation is given by:

$$P = \frac{e^{997.042 - (1223.223 \cdot \text{BPDMEAN})}}{1 + e^{997.042 - (1223.223 \cdot \text{BPDMEAN})}} \quad (6)$$

This analysis was performed using the SigmaStat (Systat Software, Inc. Richmond, CA) statistical software package.

2.5. Box plots

The data are presented in box plots. The bottom line of the rectangular box represents the 25 percentile of the data population while the top line of the box represents the 75 percentile. The lines inside the box represent the median and the mean values. Similarly the bottom cross line represents the 5 percentile and the top cross line represents the 95 percentile (for example see Fig. 1).

3. Results and discussion

3.1. Experiments with lymphoblasts

Experimental results suggested that the fluorescence intensity of the membrane potential dye in lymphoblasts from bipolar patients was significantly different from that in lymphoblasts from siblings and normal controls. We also measured the ratio of fluorescence intensity of the membrane potential dye in the K⁺-free buffer to that of the K⁺-containing (reference) buffer. The ratio in unaffected cells was significantly different from that of affected cells. This result formed the basis for using the K⁺-containing buffer as the reference buffer and the K⁺-free buffer as the comparative buffer. To augment the difference in ratio between bipolar and non-bipolar cells we incubated these cells in ethacrynate that affects the




Fig. 1. This figure shows the summary of all the data collected using whole blood samples during the clinical trials. A total of 67 patient samples were tested. There were 40 negatives (non bipolar) samples and 27 positives (bipolar I) samples. Statistical analysis using the Student's *t*-test shows that the Bipolar I group is significantly different from the non-bipolar group with a $p < 0.001$ and $t = 13$. The data are presented in box plots. The bottom line of the rectangular box represents the 25 percentile of the data population while the top line of the box represents the 75 percentile. The lines inside the box represent the median and the mean values. Similarly the bottom cross line represents the 5 percentile and the top cross line represents the 95 percentile.

ionic gradients (Rapeport et al., 1986). The fluorescent intensity ratio (fluorescent intensity with ethacrynate/fluorescent intensity without ethacrynate) was measured in reference buffer and in K^+ -free buffer. The relative intensity ratio was determined by dividing the fluorescent intensity ratio in the K^+ -free buffer by the ratio of intensities in the reference buffer. Both the buffers contained ethacrynate in these experiments. The relative intensity ratio of the affected cells was significantly higher than that of the unaffected cells by the *t*-test.

Discussion: Ethacrynate (a diuretic), is shown to increase the intracellular sodium and decreases the intracellular potassium (Rapeport et al., 1986). The increase in the intracellular sodium is known to activate the sodium pump activity to pump the extra sodium out of the cell. Thus, the addition of ethacrynate improved the differences between the membrane potential ratio in the blood cells from the affected patients and that in the unaffected patients. Li and El-Mallakh found that the ethacrynate has a differential effect on the Na^+ , K^+ -ATPase regulation in the lymphoblasts from the bipolar patients compared to the cells from the psychiatrically normal controls (Li and el Mallakh, 2004). (The supporting experimental data discussed in this section may be obtained from the corresponding author).

3.2. Clinical trial results and discussion

3.2.1. Blind trials

During the blind trial the person who performed the membrane potential measurements knew only the sample identification number and not the patient history or the diagnosis. The mean ratio is calculated by performing the tests a minimum of six to twelve times and taking an average of the data points.

Fig. 1 shows a summary of the blind test results. The *t*-test indicates a significant difference among these two groups ($p < 0.001$, $t = 13$). Descriptive statistics show that the median value of the mean ratios for the non-bipolar population is 0.858 whereas that for the bipolar I population is 0.771 and that the mean value for the non-bipolar population is 0.862 while that for the bipolar I population was 0.770. These values are very close to the median values for each of these groups. The coefficient of variation ranged from 3.5 to 4.5 in all these tests. A logistic regression analysis was performed with bipolar diagnosis as outcome and the mean membrane potential ratios as the predictor. The predictor model was statistically reliable with a likelihood ratio statistic of 56.227.

Seventeen of the bipolar patients were on lithium while 9 were on valproate and one was on topiramate after

electroconvulsive therapy. Two of the bipolar patients were diabetics. No significant effect of these medications on these limited tests was observed. We interpret these medication results to suggest that under the conditions used in the measurement of membrane potential (30 μ l blood in 9 ml buffer; 300-fold dilution), the effect of medications including lithium on the membrane potential appears to be minimal. We have collected additional test results using a plate reader for 20 patients on lithium during the test and 17 un-medicated patients confirming these results (unpublished data on file). A comparison of the specificity and sensitivity of the results from this trial for the bipolar I group with those for schizophrenia and unipolar groups is discussed below.

3.2.2. Specificity and sensitivity

Results: Specificity is the ability to identify those who do not have the disease (Dawson and Trapp, 2004). Out of a control population (those with no known mental illness) of 18, all of them were diagnosed as negative. The specificity in identifying controls was 100% as shown in Table 2. The specificity for the overall non-bipolar population (including controls, schizophrenics and unipolars) was 87.5% (35 out of 40) as shown in Table 2. Among the schizophrenic patients, the test diagnosed 8 out of 10 correctly indicating a specificity of 80%. The specificity for the unipolar patients was 75% (9 out of 12).

Table 2
Sensitivity and specificity for the clinical trial


Summary of blind tests for bipolar disorder I	
Total samples tested:	67
Total positives:	27
Total negatives:	40
Diagnostic blind test results	
Total negatives	40
True negatives	35
Specificity	87.5%
Total controls	18
True controls	18
Specificity	100%
Total schizophrenics	10
True schizophrenics	8
Specificity	80%
Total unipolars	12
True unipolars	9
Specificity	75%
Total bipolar I	27
True bipolar I	20
Sensitivity*	74%

*Note: Absence of a gold standard for diagnosis of bipolar disorder I makes the sensitivity estimate unclear.

Sensitivity is defined as the test's ability to detect the illness among the patients who actually have the disease (Dawson and Trapp, 2004). Among the population of 27 bipolar I patients, 21 were true positives as per the blood test. Hence the sensitivity of the test was 78%. However the absence of a gold standard for bipolar disorder I makes the estimate of sensitivity unclear.

Discussion: A comparison of the diagnostic blood test with 16 other tests currently being used to diagnose various other diseases indicates (Cetin et al., 2001; Wallach, 2000; Okegawa et al., 2000; Kertai et al., 2003;

Shlipak et al., 1999; Liu et al., 2003; Yu et al., 2003; Marchena et al., 2003; Matsuda et al., 1991; Joo et al., 2003; Vrublevskii et al., 2003; Mathiesen et al., 1998; Zeng et al., 2003; Hirose et al., 1999; Montine et al., 2001; Montgomery et al., 2000) that some tests have high specificity with low sensitivity whereas others have high sensitivity with low specificity. For example, the diagnostic test for osteoporosis (Cetin et al., 2001) has a sensitivity of only 21% whereas it has a specificity of 95% as compared to the test for systemic lupus erythematosus using antinuclear antigen which has a high sensitivity of 95% with a low specificity of only 50%. In the latter test, low specificity makes it somewhat less useful (Wallach, 2000). Caution is appropriate in comparing the bipolar I test with other well established tests using large number of subjects.



Mean Ratio	Percent Probability
0.67	0.00
0.665	0.01
0.66	0.03
0.655	0.14
0.65	0.64
0.645	2.86
0.644	3.84
0.643	5.13
0.642	6.83
0.64	11.86
0.635	38.04
0.63	73.69
0.625	92.74
0.62	98.31
0.615	99.63
0.61	99.92
0.605	99.98
0.6	100.00
0.59	100.00
0.58	100.00

Fig. 2. The binomial logistic regression model can be used to calculate the probability that the "patient" is bipolar I or not. The probability is calculated using the Eq. (6) of the text as a function of the mean ratio of membrane potentials. This relationship is shown in this figure as well as in the accompanying table for convenient use by psychiatrists.

4. Possible use of membrane potentials in diagnostics

The following procedure may be used to diagnose an individual patient. The patient's blood cell sample is tested as described. Six to twelve values of fluorescence intensities in K^+ -free buffer containing ethacrynate are compared to the same number of fluorescence intensities in K^+ -containing buffer without ethacrynate. The mean value of these ratios may be used to diagnose this particular patient by using predictive probability Eq. (6) derived from the logistic regression of a non-bipolar group and a bipolar I group. A plot of these probabilities as a function of BPDMEAN mean ratios is shown in Fig. 2 along with a table for these values. The probability, P , is 1 for a patient whose BPDMEAN ratio is 0.77 meaning that the probability the patient has bipolar disorder I is 100% according to this test. Thus this patient is diagnosed to be bipolar I by this test.

5. Further clinical trials needed

The clinical trial discussed in this paper is an essential first step toward further expanded clinical trials that are needed to cover the entire spectrum of factors including:

1. Children and adolescents,
2. Effect of medications,
3. Post-diagnostic evaluation of false positives and false negatives,
4. Larger sample size,
5. Balanced mix of patient demographics,
6. Participation of more psychiatrists in the evaluation process,
7. Inclusion of BPD II and ADHD,
8. Evaluation of trait and state influences and
9. Optimization of test parameters.

6. Conclusions

The above studies show that the membrane potentials provide a useful diagnostic marker for bipolar disorder I. This could be demonstrated by regulating the potassium and sodium gradients through chemical means. The clinical trials indicate that the measurement of membrane potentials of whole blood samples could be used for differentiating the bipolar I patients from the non-bipolar patients. The specificity of the test was 87.5% and the sensitivity was 78%. These values compare well with several other currently used diagnostic tests of several diseases. Further clinical trials are needed to improve the sensitivity and reliability of this test taking into consideration the multitude of factors affecting the bipolar disorder I. Additional research is also needed to understand the mechanisms of membrane potential regulation in cells from bipolar patients which may lead to an understanding of the pathogenesis of this illness.

Acknowledgments

The inpatient blood samples were provided by the Department of Psychiatry, University of Maryland, under a grant from the Maryland Technology Development Corporation, a quasi-state body (TEDCO Grant No. 102203). The outpatient samples were provided by Sharon A. Murphy, M.D. a clinical psychiatrist in Columbia, MD.

Rif S. El-Mallakh, M.D., Director of Mood Disorders Program, School of Medicine, at University of Louisville, KY reviewed this manuscript and suggested several improvements. Oliver W. Hill, Jr., Ph.D. Professor and Chair, Department of Psychology, Virginia State University, Petersburg, VA suggested and assisted with the multiple regression technique used in this paper. Rama Thiruvengadam, M.D. a clinical psychiatrist in Kona, HI suggested many useful editorial changes. Douglas Woodruff, M.D. (who was the Psychiatric Editor of Stedman's Medical Dictionary, the 27th edition, and is acting in the same capacity for the present edition in progress) has also edited the revised manuscript. A patent based on the findings of this paper is pending with US patent office.

References

- Bowden, C.L., 2002. Diagnosis of bipolar disorders: focus on bipolar disorder I and bipolar disorder. *MedGenMed* 4, 17.
- Buss, T.J., Li, R., Peiper, S.C., el Mallakh, R.S., 1996. Lymphoblastoid transmembrane potential in bipolar patients, their siblings, and unrelated healthy comparison subjects. *Psychiatry Res.* 59, 197–201.
- Cetin, A., Erturk, H., Celiker, R., Sivri, A., Hascelik, Z., 2001. The role of quantitative ultrasound in predicting osteoporosis defined by dual X-ray absorptiometry. *Rheumatol. Int.* 20, 55–59.
- Cherry, L., Swann, A.C., 1994. Cation transport mediated by Na⁺/K⁺(+)-adenosine triphosphatase in lymphoblastoma cells from patients with bipolar I disorder, their relatives, and unrelated control subjects. *Psychiatry Res.* 53, 111–118.
- Dawson, B., Trapp, R.G., 2004. Basic and Clinical Biostatistics, 4th ed. Lange Medical Books–McGraw-Hill, Medical Pub. Division, New York.
- el Mallakh, R.S., Wyatt, R.J., 1995. The Na⁺/K⁺-ATPase hypothesis for bipolar illness. *Biol. Psychiatry* 37, 235–244.
- el Mallakh, R.S., Li, R., Worth, C.A., Peiper, S.C., 1996. Leukocyte transmembrane potential in bipolar illness. *J. Affect. Disord.* 41, 33–37.
- Ghaemi, S.N., Boiman, E.E., Goodwin, F.K., 2000. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. *J. Clin. Psychiatry* 61, 804–808.
- Hirose, K., Wener, M.H., Duckert, L.G., 1999. Utility of laboratory testing in autoimmune inner ear disease. *Laryngoscope* 109, 1749–1754.
- Hirschfeld, R.M., Lewis, L., Vornik, L.A., 2003. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-depressive Association 2000 survey of individuals with bipolar disorder. *J. Clin. Psychiatry* 64, 161–174.
- Joo, K.R., Kim, H.d., Park, J.H., Bang, S.J., Shin, J.W., Park, N.H., et al., 2003. The role of bile carcinoembryonic antigen in diagnosing bile duct cancer. *J. Korean Med. Sci.* 18, 855–858.
- Kertai, M.D., Boersma, E., Bax, J.J., Heijnenbroek-Kal, M.H., Hunink, M.G., L'italien, G.J., et al., 2003. A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery. *Heart* 89, 1327–1334.
- Li, R., el Mallakh, R.S., 2004. Differential response of bipolar and normal control lymphoblastoid cell sodium pump to ethacrynic acid. *J. Affect. Disord.* 80, 11–17.
- Lish, J.D., Dime-Meenan, S., Whybrow, P.C., Price, R.A., Hirschfeld, R.M., 1994. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. *J. Affect. Disord.* 31, 281–294.
- Liu, H.H., Huang, T.W., Chen, H.L., Wang, T.H., Lin, J.T., 2003. Clinicopathologic significance of immunohistochemical fecal occult blood test in subjects receiving bidirectional endoscopy. *Hepatogastroenterology* 50, 1390–1392.
- Looney, S.W., el Mallakh, R.S., 1997. Meta-analysis of erythrocyte Na⁺/K⁺-ATPase activity in bipolar illness. *Depress. Anxiety* 5, 53–65.
- Marchena, J., Acosta, M.A., Garcia-Anguiano, F., Simpson, H., Cruz, F., 2003. Use of the preoperative levels of CEA in patients with colorectal cancer. *Hepatogastroenterology* 50, 1017–1020.
- Mathiesen, M.J., Christiansen, M., Hansen, K., Holm, A., Asbrink, E., Theisen, M., 1998. Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. *J. Clin. Microbiol.* 36, 3474–3479.
- Matsuda, M., Shimizu, Y., Chikamatsu, E., Takayanagi, K., Ishigure, H., Murakami, S., et al., 1991. Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer. *Nippon Geka Gakkai Zasshi* 92, 716–721.
- Montgomery Jr, E.B., Lyons, K., Koller, W.C., 2000. Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery. *Mov. Disord.* 15, 474–478.

- Montine, T.J., Kaye, J.A., Montine, K.S., McFarland, L., Morrow, J.D., Quinn, J.F., 2001. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. *Arch. Pathol. Lab. Med.* 125, 510–512.
- Nicholls, D.G., Ward, M.W., 2000. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. *Trends Neurosci.* 23, 166–174.
- Okegawa, T., Noda, H., Nukahara, K., Higashihara, E., 2000. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. *Eur. Urol.* 38, 380–387.
- Pratap, P.R., Novak, T.S., Freedman, J.C., 1990. Two mechanisms by which fluorescent oxonols indicate membrane potential in human red blood cells. *Biophys. J.* 57, 835–849.
- Rapeport, W.G., Aronson, J.K., Grahame-Smith, D.G., Harper, C., 1986. The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes after incubation for 3 days. *Br. J. Clin. Pharmacol.* 22, 275–279.
- Rottenberg, H., Wu, S., 1998. Quantitative assay by flow cytometry of the mitochondrial membrane potential in intact cells. *Biochim. Biophys. Acta* 1404, 393–404.
- Shlipak, M.G., Lyons, W.L., Go, A.S., Chou, T.M., Evans, G.T., Browner, W.S., 1999. Should the electrocardiogram be used to guide therapy for patients with left bundle-branch block and suspected myocardial infarction? *JAMA* 281, 714–719.
- Suppes, T., Leverich, G.S., Keck, P.E., Nolen, W.A., Denicoff, K.D., Altshuler, L.L., et al., 2001. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. *J. Affect. Disord.* 67, 45–59.
- Tabachnick, B., Fidell, L., 2001. *Using Multivariate Statistics*. Allyn & Bacon, Boston.
- Thiruvengadam, A., 2001. Effect of lithium and sodium valproate ions on resting membrane potentials in neurons: an hypothesis. *J. Affect. Disord.* 65, 95–99.
- Thiruvengadam, A., 2004. The Recent Studies On The Electrobiochemical Aspects Of Bipolar Disorder. In: Brown, M.R. (Ed.), *Focus on Bipolar Disorder Research*. Nova Science Publishers, New York, pp. 15–35.
- Vrublevskii, A.V., Boshchenko, A.A., Karpov, R.S., 2003. Stress echocardiography with the use of impulse wave tissue Doppler technology in diagnosis and quantitative evaluation of concealed myocardial ischemia. *Kardiologija* 43, 10–17.
- Waczulikova, I., Sikurova, L., Bryszewska, M., kawiecka, R., Carsky, J., Ulicna, O., 2000. Impaired erythrocyte transmembrane potential in diabetes mellitus and its possible improvement by resorcyldene aminoguanidine. *Bioelectrochemistry* 52, 251–256.
- Wallach, J.B., 2000. *Interpretation of diagnostic tests*, 7th ed. Lippincott Williams & Wilkins, Philadelphia.
- Wood, A.J., Smith, C.E., Clarke, E.E., Cowen, P.J., Aronson, J.K., Grahame-Smith, D.G., 1991. Altered in vitro adaptive responses of lymphocyte Na⁺,K⁺-ATPase in patients with manic depressive psychosis. *J. Affect. Disord.* 21, 199–206.
- Yu, B.K., Kuo, B.I., Yen, M.S., Twu, N.F., Lai, C.R., Chen, P.J., et al., 2003. Improved early detection of cervical intraepithelial lesions by combination of conventional Pap smear and speculoscopy. *Eur. J. Gynaecol. Oncol.* 24, 495–499.
- Zeng, X., Ai, M., Tian, X., Gan, X., Shi, Y., Song, Q., et al., 2003. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. *J. Rheumatol.* 30, 1451–1455.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.